GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocular Therapeutix Inc (FRA:0OT) » Definitions » Cyclically Adjusted Revenue per Share

Ocular Therapeutix (FRA:0OT) Cyclically Adjusted Revenue per Share : €0.28 (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Ocular Therapeutix Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Ocular Therapeutix's adjusted revenue per share for the three months ended in Mar. 2024 was €0.103. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €0.28 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Ocular Therapeutix's average Cyclically Adjusted Revenue Growth Rate was 25.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2024-05-23), Ocular Therapeutix's current stock price is €5.618. Ocular Therapeutix's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €0.28. Ocular Therapeutix's Cyclically Adjusted PS Ratio of today is 20.06.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of Ocular Therapeutix was 38.39. The lowest was 7.80. And the median was 17.52.


Ocular Therapeutix Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Ocular Therapeutix's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocular Therapeutix Cyclically Adjusted Revenue per Share Chart

Ocular Therapeutix Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 0.21 0.26

Ocular Therapeutix Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.23 0.24 0.25 0.26 0.28

Competitive Comparison of Ocular Therapeutix's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Ocular Therapeutix's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ocular Therapeutix's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ocular Therapeutix's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Ocular Therapeutix's Cyclically Adjusted PS Ratio falls into.



Ocular Therapeutix Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Ocular Therapeutix's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.103/131.7762*131.7762
=0.103

Current CPI (Mar. 2024) = 131.7762.

Ocular Therapeutix Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.023 100.560 0.030
201409 0.007 100.428 0.009
201412 0.019 99.070 0.025
201503 0.018 99.621 0.024
201506 0.018 100.684 0.024
201509 0.015 100.392 0.020
201512 0.016 99.792 0.021
201603 0.017 100.470 0.022
201606 0.016 101.688 0.021
201609 0.017 101.861 0.022
201612 0.019 101.863 0.025
201703 0.016 102.862 0.020
201706 0.013 103.349 0.017
201709 0.015 104.136 0.019
201712 0.014 104.011 0.018
201803 0.008 105.290 0.010
201806 0.015 106.317 0.019
201809 0.011 106.507 0.014
201812 0.011 105.998 0.014
201903 0.010 107.251 0.012
201906 0.013 108.070 0.016
201909 0.014 108.329 0.017
201912 0.041 108.420 0.050
202003 0.045 108.902 0.054
202006 0.024 108.767 0.029
202009 0.073 109.815 0.088
202012 0.085 109.897 0.102
202103 0.071 111.754 0.084
202106 0.118 114.631 0.136
202109 0.121 115.734 0.138
202112 0.132 117.630 0.148
202203 0.145 121.301 0.158
202206 0.141 125.017 0.149
202209 0.157 125.227 0.165
202212 0.161 125.222 0.169
202303 0.161 127.348 0.167
202306 0.180 128.729 0.184
202309 0.166 129.860 0.168
202312 0.150 129.419 0.153
202403 0.103 131.776 0.103

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Ocular Therapeutix  (FRA:0OT) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Ocular Therapeutix's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=5.618/0.28
=20.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of Ocular Therapeutix was 38.39. The lowest was 7.80. And the median was 17.52.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Ocular Therapeutix Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Ocular Therapeutix's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Ocular Therapeutix (FRA:0OT) Business Description

Industry
Traded in Other Exchanges
Address
24 Crosby Drive, Bedford, MA, USA, 01730
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Ocular Therapeutix aims to offer medication to replace the existing eye-drop therapy regimen, with the aim of lasting weeks or months with a one-time product application. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.

Ocular Therapeutix (FRA:0OT) Headlines

No Headlines